Verastem, Inc. VSTM
NASDAQ · United States · Health Technology
$7.70-0.20 (-2.53%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
BOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
BOSTON, September 24, 2026--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.